Peripherally restricted opioid agonists as novel analgesic agents

Current Pharmaceutical Design

Volumn 10, Issue 7, 2004, Pages 743-757

  DeHaven Hudkins, D L ^a   Dolle, R E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; 3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ADL 01 0398; ADL 010398; ADL 10 0101; ADL 10 0102; ADL 10 0116; ADL 100101; ADL 100102; ADL 100116; ANALGESIC AGENT; ASIMADOLINE; BCH 2687; CODEINE; DELTA OPIATE RECEPTOR AGONIST; ENADOLINE; ENKEPHALIN DERIVATIVE; FE 200665; GR 129083; GR 94839; IMODIUM AD; KAPPA OPIATE RECEPTOR AGONIST; LEF 553; LOPERAMIDE; MORPHINE; MU OPIATE RECEPTOR AGONIST; MULTIDRUG RESISTANCE PROTEIN; NALOXONE; OPIATE AGONIST; OPIATE RECEPTOR; SPIRADOLINE; TYROSYL DEXTRO ARGINYLPHENYLALANYLPHENYLALANINE; UK 321130; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANTINOCICEPTION; BRAIN; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DYSPHORIA; HUMAN; HYDROPHILICITY; IN VIVO STUDY; INFLAMMATION; IRRITABLE COLON; LIPOPHILICITY; NONHUMAN; POSTOPERATIVE PAIN; PREDICTION; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SEDATION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VISCERAL PAIN;

ANALGESICS, OPIOID; ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR CONFORMATION; PAIN MEASUREMENT; PERIPHERAL NERVES; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1442276958     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453036     Document Type: Review

References (71)

1. Hargreaves KM, Joris JL. The peripheral analgesic effects of opioids. APS Journal 1993; 2: 51-9.
2. Stein C. The control of pain in peripheral tissue by opioids. New Engl J Med 1995; 332: 1685-90.
3. Nagasaka H, Awad H, Yaksh TL. Peripheral and spinal actions of opioids in the blockade of the autonomic response evoked by compression of the inflamed knee joint. Anesthesiology 1996; 85: 808-16.
4. Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 1989; 248: 1269-75.
5. Antonijevic I, Mousa SA, Schafer M, Stein C. Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci 1995; 15: 165-72.
6. Hassan AHS, Ableitner A, Stein C, Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 1993; 55: 185-95.
7. Coggeshall RE, Zhou S, Carlton SM. Opioid receptors on peripheral sensory axons. Brain Res 1997; 764: 126-32.
8. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48: 567-92.
9. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. p-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
10. Jonker JW, Wagenaar E, van Deemter L, Gottschlich R, Bender HM, Dasenbrock J, et al. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol 1999; 127: 43-50.
11. Foster RS, Jenden DJ, Lomax P. A comparison of the pharmacologic effects of morphine and N-methyl morphine. J Pharmacol Exp Ther 1967; 157: 185-95.
12. Smith TW, Buchan P, Parsons DN, Wilkinson S. Peripheral antinociceptive effects of N-methyl morphine. Life Sci 1982; 31: 1205-8.
13. Oluyomi AO, Hart SL, Smith TW. Differential antinociceptive effects of morphine and methylmorphine in the formalin test. Pain 1992; 49: 415-8.
14. DeHaven-Hudkins DL, Cortes Burgos L, Cassel JA, Daubert JD, DeHaven RN, Mansson E, et al. Loperamide (ADL 2-1294), an opiate antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 1999; 289: 494-502.
15. Nozaki-Taguchi N, Awad H, Yaksh TL. Peripheral and spinal actions of opioids in the blockade of the autonomic response evoked by compression of the inflamed knee joint. Anesthesiology 1996; 85: 808-16.
16. Niemegeers CJE, Colpaert FC, Awouters FHL. Pharmacology and antidiarrheal effect of loperamide. Drug Dev Res 1981; 1: 1-20.
17. Collins JG, Shimada SG, Krocheski K. Profound analgesia produced in rats by a mu opioid agonist with peripheral selectivity. Anesth Analg 1998; 86: S266.
18. Swedberg MDB, Alari L, Stahlberg M, Ask A-L, Ericson A-C. Analgesic and discriminative effects of LEF553, a peripherally acting μ-opioid. Soc Neurosci Abstr 1998; 24: 888.
19. Krondahl E, Orzechowski A, Ekstrom G, Lennemäs H. Rat jejunal permeability and metabolism of μ-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharmaceut Res 1997; 14: 1780-5.
20. Binder W, Machelska H, Mousa S, Schmitt T, Rivière PJ, Junien JL, et al. Analgesic and antiiinflammatory effects of two novel κ-opioid peptides. Anesthesiology 2001; 94: 1034-44.
21. Gottshall SL, Cassel JA, Cortes Burgos L, Daubert JD, DeHaven RN, Koblish M, et al. Antinociception produced by ADL 10-0101, a novel peripheral κ opioid receptor agonist, in models of inflammatory hyperalgesia. Soc Neurosci Abstr 1999; 25: 1221.
22. Gottshall SL, Cassel JA, Daubert JD, DeHaven RN, Koblish M, Kumar V, et al. ADL 10-0116, a peripherally restricted κ opioid receptor agonist with prolonged duration of action. Soc Neurosci Abstr 2000; 26: 914.
23. Long SL, Cassel JA, Daubert JD, DeHaven RN, Gottshall SL, Koblish M, et al. Pharmacological profile of ADL 01-398, a novel, peripherally restricted κ opioid receptor agonist, in models of nociception and sedation in the rat and mouse. Soc Neurosci Abstr 2000; 26: 914.
24. Rogers H, Birch PJ, Harrison SM, Palmer E, Manchee GR, Judd DB, et al. GR94839, a κ-opioid agonist with limited access to the central nervous system, has antinociceptive activity. Br J Pharmacol 1992; 106: 783-9.
25. Gottshall SL, DeHaven-Hudkins DL. Effects of peripheral administration of δ opioid receptor agonists in models of inflammatory pain. Soc Neurosci Abstr 1997; 23: 1018.
26. Maw GN. Discovery of non-peptide δ-opioid receptor agonists. 221st National Meeting of the American Chemical Society, San Diego, CA; American Chemical Society: Washington, DC, 2001; MEDI 168.
27. Dionne RA, Dobbins KR, Hargreaves KM. Evaluation of a kappa opioid agonist, spiradoline, in comparison to morphine and placebo in the oral surgery model. Clin Pharmacol Ther 1991; 49: 183.
28. Pande AC, Pyke RE, Greiner M, Cooper SA, Benjamin R, Pierce MW. Analgesic efficacy of the κ-receptor agonist, enadoline, in dental surgery pain. Clin Neuropharmacol 1996; 19: 92-7.
29. Pande AC, Pyke RE, Greiner M, Wideman GL, Benjamin R, Pierce MW. Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin Neuropharmacol 1996; 19: 451-6.
30. Shaw JS, Carroll JA, Alcock P, Main BG. ICI 204448: a κ-opioid agonist with limited access to the CNS. Br J Pharmacol 1989; 96: 986-92.
31. Birch PJ, Hayes AG, Johnson MR, Lea TA, Murray PJ, Rogers H, et al. Preparation and evaluation of some hydrophilic phenylacetylpiperazines as peripherally selective κ-opioid receptor agonists. Bioorg Med Chem Lett 1992; 2: 1275-8.
32. Barber A, Bartoszyk GD, Bender HM, Gottschlich R, Greiner HE, Harting J, et al. A pharmacological profile of the novel, peripherally-selective κ-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994; 113: 1317-27.
33. Bickel A, Dorfs S, Schmelz M, Forster C, Uhl W, Handwerker HO. Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain 1998; 76: 317-25.
34. Kramer HJ, Uhl W, Ladstetter B, Backer A. Influence of asimadoline, a new κ-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br J Clin Pharmacol 2000; 50: 227-35.
35. Machelska H, Pfluger M, Weber W, Piranvisseh-Volk M, Daubert JD, DeHaven R, et al. Peripheral effects of the κ-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 1999; 290: 354-61.
36. Saif I, Shimada S, Collins JG. Hyperalgesia produced by a peripherally limited kappa-opioid agonist, EMD 61753, in normal and hyperalgesic tissue of rats. Soc Neurosci Abstr 2000; 26: 2185.
37. Shimada SG, Fitzgerald JF, Collins JG, Naulty JS. Local administration of the kappa agonist, EMD 61753, in normal and thermally injured tissue. 9th World Congress on Pain 1999; August 22-27, Vienna, Austria.
38. Gottshall SL, Bartilomo TA, Cassel JA, Daubert JD, DeHaven RN, Greiner SL, et al. Antinociception produced by ADL 10-0102, a novel kappa opioid receptor agonist, in models of inflammatory and acute pain. Soc Neurosci Abstr 2001; 27: 614.15.
39. Guo D, Kumar V, Maycock A, DeHaven RN, Daubert JD, Cassel JA, et al. Synthesis and evaluation of novel peripheral κ opioid receptor agonists. 219th National Meeting of the American Chemical Society, San Francisco, CA; American Chemical Society: Washington, DC, 2000; MEDI 263.
40. Koblish M, Little PJ, Gottshall SL, Marella M, Kumar V, DeHaven-Hudkins DL. Profile of ADL 10-0101 in models of central κ opioid agonist activity in the rat and mouse. Soc Neurosci Abstr 1999; 25: 1221.
41. Kumar V, Marella MA, Cortes Burgos L, Chang A-C, Cassel JA, Daubert JD, et al. Arylacetamides as peripherally restricted kappa opioid agonists. Bioorg Med Chem Lett 2000; 10: 2567-70.
42. Little PJ, Koblish M, Gottshall SL, Long SL, Kumar V, Marella M, et al. Differential effects of peripheral kappa opiate agonists in the rotarod and diuresis assays. NIDA Research Monograph 1999; 180: 247.
43. Vanderah TW, Rivière PJM, Houghten R, Schteingart C, Trojnar J, Junien J-L, et al. Novel D-amino acid tetrapeptides demonstrate unprecedented kappa-opioid receptor selectivity and peripheral antinociceptive activity. Soc Neurosci Abstr 1999; 25: 931.
44. Wisniewski K, Sueiras-Diaz J, Schteingart C, Galyean R, Houghten R, Vanderah T, et al. Long acting, selective, peripheral kappa agonists. Proceedings of the 26th European Peptide Symposium, Montpellier, France, September 10-15, 2000.
45. McMahon SB, Koltzenburg M. Itching for an explanation. Trends Neurosci 1992; 15: 497-501.
46. Cowan A, Kehner GB. Antagonism by opioids of Compound 48/80-induced scratching in mice. Br J Pharmacol 1997; 122: 169P.
47. Kuraishi Y, Nagasawa T, Hayashi K, Satoh M. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 1995; 275: 229-33.
48. Kehner GB, Gaul F, Zhang WY, Daubert JD, Cassel JA, DeHaven RN, et al. Stereoselective antipruritic effects of enadoline and GR 94839 in mice. FASEB J 1999; 13: A801.
49. Kehner GB, DeHaven-Hudkins DL, Little PJ, Koblish M, Kumar V, Marella M, et al. Antinociceptive and antipruritic potencies of peripherally selective kappa agonists in mice. NIDA Research Monogmph 1999; 180: 246.
50. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998; 285: 707-15.
51. Sengupta JN, Su X, Gebhart GF. κ, but not μ or δ, opioids attenuate responses to distension of afferent fibers innervating the rat colon. Gastroenterology 1996; 111: 968-80.
52. Joshi SK, Su X, Porreca F, Gebhart GF. κ-opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action. J Neurosci 2000; 20: 5874-9.
53. Sandner-Kiesling A, Pan H-L, Chen S-R, James RL, DeHaven-Hudkins DL, Dewan DM, et al. Effect of kappa opioid agonists on visceral nociception induced by uterine distension in rats. Pain 2002; 96: 13-22.
54. Herz A, Teschemacher H-J. Activities and sites of antinociceptive action of morphine-like analgesics and kinetics of distribution following intravenous, intracerebral and intraventricular application. Adv Drug Res 1971; 6: 79-119.
55. Blackburn TP, Borkowski KR, Friend J, Rance MJ. On the mechanism of κ-opioid-induced diuresis. Br J Pharmacol 1986; 89: 593-8.
56. Leander JD. A kappa opioid effect: increased urination in the rat. J Pharmacol Exp Ther 1983; 224: 89-94.
57. Salas SP, Roblero J, Ureta H, Huidobro-Toro JP. Diuretic effect of bremazocine, a kappa-opioid with central and peripheral sites of action. J Pharmacol Exp Ther 1989; 250: 992-9.
58. Brown CH, Ludwig M, Leng G. Kappa-opioid regulation of neuronal activity in the rat supraoptic nucleus in vivo. J Neurosci 1998; 18: 9480-8.
59. Weiss ML, Cobbett P. Intravenous injection of Evans Blue labels magnocellular neuroendocrine cells of the rat supraoptic nucleus in situ and after dissociation. Neuroscience 1992; 48: 383-95.
60. Leander JD, Hart JC, Zerbe RL. Kappa agonist-induced diuresis: evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels. J Pharmacol Exp Ther 1987; 242: 33-9.
61. Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC, et al. CI-977, a novel and selective agonist for the κ-opioid receptor. Br J Pharmacol 1990; 101: 183-9.
62. Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagopalan R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 1994; 34: 1126-32.
63. Wuster M, Herz A. Opiate agonist action of antidiarrheal agents in vitro and in vivo - findings in support for selective action. Naun-Schmied Arch Pharmacol 1978; 301: 187-94.
64. DeHaven-Hudkins DL, Gauntner EK, Gottshall SL, Koblish M, Kumar V, Little PJ, et al. Peripheral restriction of κ opioid receptor agonists as defined by pharmacokinetic parameters correlates with behavioral indices of sedation in the rat. Soc Neurosci Abstr 2000; 26: 915.
65. Murphy DM, Koblish M, Gauntner EK, Little PJ, Gottshall SL, Garver DD, et al. A screening process for in vivo assessment of blood-brain barrier penetration for kappa (κ) opioid receptor agonists. International Society for the Study of Xenobiotics, Indianapolis, IN, October 24-28, 2000.
66. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, et al. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol Pharmacol 1994; 45: 330-4.
67. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat κ opioid receptor reveals sequence similarities to the μ and δ opioid receptors. Biochem J 1993; 295: 625-8.
68. Meng F, Hoversten MT, Thompson RC, Taylor L, Watson SJ, Akil H. A chimeric study of the molecular basis of affinity and selectivity of the K and the δ opioid receptors. J Biol Chem 1995; 270: 12730-6.
69. Graham GG, Graham RI, Day RO. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr Pharm Design 2002; 8(12): 1063-75.
70. Ozturk Y. Kinin receptors and their antagonists as novel therapeutic agents. Curr Pharm Design 2001; 7(2): 135-61.
71. Wong MG, Tehan BG, Lloyd EJ. Molecular mapping in the CNS. Curr Pharm Design 2002; 8(17): 1547-70.